Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

Zobair M. Younossi, Aaron B. Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer – 28 December 2015 – Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonalcoholic steatohepatitis (NASH). PubMed/MEDLINE were searched from 1989 to 2015 for terms involving epidemiology and progression of NAFLD.

Monoclonal anti‐envelope antibody AP33 protects humanized mice against a patient‐derived hepatitis C virus challenge

Isabelle Desombere, Samira Fafi‐Kremer, Freya Van Houtte, Patrick Pessaux, Ali Farhoudi, Laura Heydmann, Lieven Verhoye, Sarah Cole, Jane A. McKeating, Geert Leroux‐Roels, Thomas F. Baumert, Arvind H. Patel, Philip Meuleman – 28 December 2015 – End‐stage liver disease (ESLD) caused by hepatitis C virus (HCV) infection is a major indication for liver transplantation. However, immediately after transplantation, the liver graft of viremic patients universally becomes infected by circulating virus, resulting in accelerated liver disease progression.

Liver transplantation in the mouse: Insights into liver immunobiology, tissue injury, and allograft tolerance

Shinichiro Yokota, Osamu Yoshida, Yoshihiro Ono, David A. Geller, Angus W. Thomson – 28 December 2015 – The surgically demanding mouse orthotopic liver transplant model was first described in 1991. It has proved to be a powerful research tool for the investigation of liver biology, tissue injury, the regulation of alloimmunity and tolerance induction, and the pathogenesis of specific liver diseases.

Subscribe to